Equity · Healthcare
TYRA
NASDAQTyra Biosciences (TYRA)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.
- Market cap
- 1.9B USD
- EPS, diluted, year to Dec 2025
- −2.01 USD
- 52-week range
- 10 USD – 40 USD
- Avg volume
- 197.2K
as of Jul 17, 2026
Have Tyra Biosciences (TYRA) insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, Tyra Biosciences insiders reported 1 open-market purchase and no sales (SEC Form 4).
Form 4, 90 days to 10 Nov 2026, newest reported trade 9 Sep 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 09 Sep 2026 | Verjee RehanDirector | Buy | 972 | 20K USD |
3 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 15 Sep 2026 | Harris ToddPresident and CEO | Award | 864 | 8K USD |
| 15 Sep 2026 | Rueb YuliyaVice President, Finance (PAO) | Award | 2,925 | 27K USD |
| 15 Sep 2026 | Fuhrman AlanChief Financial Officer | Award | 951 | 9K USD |
Which funds hold Tyra Biosciences (TYRA)?
1 of the 45 institutional funds we track reported a Tyra Biosciences position for the quarter ended 30 Sep 2026 — a combined 564K USD; the latest of those filings landed 06 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Fisher Asset Management | Trimmed | 25,766 | 564K USD | −57.2% |
What has been filed or recorded for Tyra Biosciences (TYRA)?
The filings we hold for Tyra Biosciences, newest first: 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 30 Jun 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.69 USD | |
| 30 Jun 2026 | Financials | Total assets | 383.4M USD | at period end |
| 30 Jun 2026 | Financials | Total equity | 353.7M USD | at period end |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.64 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −2.01 USD | |
| 31 Dec 2025 | Financials | Net income | −119.9M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −2.01 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.50 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.47 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.47 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −1.51 USD | |
| 30 Sep 2024 | Quarterly earnings | Q3 2024 reported | EPS −0.41 USD |
What do people ask about Tyra Biosciences (TYRA)?
What is Tyra Biosciences’ market cap?1.9B
Tyra Biosciences is worth 1.9B USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.
Have Tyra Biosciences insiders bought or sold shares recently?1 purchase
In the 90 days to 10 Nov 2026, Tyra Biosciences insiders reported 1 open-market purchase and no sales (SEC Form 4). A further 3 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Tyra Biosciences?1 of 45
1 of the 45 funds we track reported a Tyra Biosciences position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds
When did Tyra Biosciences last report earnings?−0.69
Tyra Biosciences last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −0.69 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings